Patient characteristics, treatment patterns and outcomes of patients enrolled in the Tezepelumab Patient Access Programme; a retrospective, observational medical chart review conducted in UK severe asthma centres

Trial Identifier: D5180R00027
Sponsor: AstraZeneca
Start Date: April 2024
Primary Completion Date: September 2024
Study Completion Date: September 2024

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
United Kingdom Birmingham, United Kingdom
United Kingdom Liverpool, United Kingdom
United Kingdom London, United Kingdom
United Kingdom Plymouth, United Kingdom
United Kingdom Southampton, United Kingdom